S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)

It’s Time To Nibble On These Two Recent IPOs 

It’s Time To Nibble On These Two Recent IPOs 

IPOs, Buy Them When They’re Down 

It’s hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (NASDAQ: PEPG) both IPOd in 2022 and have seen their shares plummet in the wake of the offering, not because they are poor companies or bad investments but simply because the market conditions changed. The takeaway is that now these stocks are trading well off the post-IPO highs and the analyst's quiet period is over.  The sentiment on Wall Street is that both of these stocks are buyable and should be trading at higher levels than they are. 

PepGen Has Triple-Digit Potential 

PepGen is a clinical-stage biopharma researching and producing compounds for the treatment of neuromuscular and neurological diseases. The company has several compounds in testing phases including treatments for muscular dystrophy. At least 4 analysts have come out so far with ratings and they agree, that the stock is a firm Buy with two Buy ratings and two outperform ratings. More importantly, the Marketbeat.com consensus estimate of $24.25 is more than 120% above the current price action and that target is well off of the high target. The high target of $40 was set by SVB Leerink and adds another 65% to the consensus. 


Turning to the chart, the price action is moving higher in the wake of the commentary and looks like it will continue higher. The risk now is resistance at the $12 and it may be strong based on the sharp decline in price action following the IPO. While we expect to see resistance cap gains at this level, the pause may be short-lived due to the upside potential. Even the low price target of $16 offers about 60% of upside and it is right at the top of the established range. A move to that level would be bullish but we would expect a move to new highs without another catalyst to drive it. 

It’s Time To Nibble On These Two Recent IPOs 

Bausch + Lomb, A Diversified Play On Eye Care 

Bausch + Lomb is a diversified play on healthcare, specifically, eye care, that operates in three segments including consumer products, ophthalmic pharma, and surgical. The stock price fell sharply despite opening at the low-end of its expected range which we are viewing as a deep-value entry point due to the established nature of the business. The analysts are a little less enthusiastic, rating the stock a weak Buy, but the 4 Hold-equivalent ratings are worth a Buy to us at this stage of the game.

The Marketbeat.com consensus price target is also on the tepid side compared to PepGen but this is a different kind of business and one that comes with both better visibility and far less risk. As it is, the consensus target is still more than 40% above the current price action. Turning to the chart, the price action in this stock suggests a bottom is in place at the $16.00 level but support may get retested before a new rally can begin. Longer-term, analysts at Wells Fargo see this company’s growth as supported by our aging population, the shift to contacts and daily/disposable contacts, and the company’s pipeline of ophthalmic treatments. 

It’s Time To Nibble On These Two Recent IPOs 

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Bausch + Lomb (BLCO)
2.8354 of 5 stars
$16.30flatN/AN/AModerate Buy$22.64
PepGen (PEPG)
2.3875 of 5 stars
$10.26-3.8%N/AN/ABuy$24.25
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Bausch + Lomb right now?

Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastESG - Profitably Invest Your Values

David McNatt discusses ESG investing and offers ways to avoid pitfalls and to understand exactly what kinds of companies you are buying.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.